BVS

MKT CAP:$670M

Bioventus Inc.

Market Cap

$670M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Healthcare·Medical - Devices·🇺🇸·NASDAQ

Stock Price

$10.51+$3.30 (+45.70%)

Apr 17, 2026

Company Details

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio incl...

CEO

Robert E. Claypoole

IPO Date

Feb 11, 2021

Website

www.bioventus.com

Key Metrics TTM

Revenue

$561M

+43.9% YoY

Net Income

-$96M

EPS (Diluted)

$0.19

Free Cash Flow

$75M

Revenue / Share

$8.14

Gross Margin

65.7%

Operating Margin

-16.4%

Net Margin

-17.2%

FCF Margin

13.3%

P/S

1.2x

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

Q4 2025

Mar 5, 2026

$158MEPS $0.21

Q3 2025

Nov 4, 2025

$139MEPS $0.05

Q4 2023

Mar 12, 2024

$135MEPS -$0.10

Q3 2022

Nov 21, 2022

$129MEPS $0.03

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 15	$53M	$37M	-$16M
Q1 16	$65M	$46M	-$2M
Q4 21	$130M	$88M	-$3M
Q2 22	$140M	$97M	-$3M
Q3 22	$129M	$85M	-$127M
Q4 23	$135M	$86M	$1M
Q3 25	$139M	$93M	$12M
Q4 25	$158M	$104M	$22M

Valuation

Quarter	P/S	P/E
Q1 15	—	—
Q1 16	—	—
Q4 21	—	—
Q2 22	1.3x	—
Q3 22	0.9x	—
Q4 23	0.6x	—
Q3 25	0.8x	—
Q4 25	0.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 15	-$4M	-$4M
Q1 16	$2M	-$4M
Q4 21	$13M	$10M
Q2 22	$3M	$909.0K
Q3 22	-$701.0K	-$2M
Q4 23	$10M	$10M
Q3 25	$30M	$30M
Q4 25	$38M	$37M

Capital Expenditures

Quarter	CapEx
Q1 15	$306.0K
Q1 16	$7M
Q4 21	$3M
Q2 22	$2M
Q3 22	$2M
Q4 23	$369.0K
Q3 25	$473.0K
Q4 25	$580.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 22	+141.1%	+266.8%
Q4 23	+107.1%	+99.1%
Q3 25	+6.3%	-5.3%
Q4 25	+12.5%	-5.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 15	$0	0.0%
Q1 16	$0	0.0%
Q4 21	$4M	3.3%
Q2 22	$5M	3.3%
Q3 22	$5M	3.6%
Q4 23	$0	0.0%
Q3 25	$0	0.0%
Q4 25	$3M	2.2%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 15	$3M	$37M
Q1 16	$4M	$40M
Q4 21	$7M	$81M
Q2 22	$6M	$90M
Q3 22	$5M	$79M
Q4 23	$3M	$78M
Q3 25	$3M	$78M
Q4 25	$3M	$83M

Revenue Segments

Quarter	Pain Treatments	Restorative Therapies	Surgical Solutions	International Segment	U.S. Segment
Q2 22	$64M	$40M	$37M	—	—
Q3 25	—	—	—	$15M	$123M
Q4 25	—	—	—	$18M	$139M

Revenue by Geography

Quarter	Non-US	United States
Q4 21	$15M	$115M
Q2 22	$14M	$126M
Q3 25	$15M	$123M
Q4 25	$18M	$139M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$27M	$0	$27M
Q2 22	$41M	$0	$41M
Q3 22	$34M	$0	$34M
Q4 22	$30M	$0	$30M
Q1 23	$47M	$0	$47M
Q2 23	$29M	$0	$29M
Q3 23	$27M	$0	$27M
Q4 23	$37M	$0	$37M
Q1 24	$25M	$0	$25M
Q2 24	$32M	$0	$32M
Q3 24	$43M	$0	$43M
Q4 24	$42M	$0	$42M
Q1 25	$23M	$0	$23M
Q2 25	$33M	$0	$33M
Q3 25	$42M	$0	$42M
Q4 25	$51M	$0	$51M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 15	57M	—	—
Q1 16	56M	-2.1%	—
Q4 21	55M	-1.6%	—
Q2 22	61M	+12.3%	—
Q3 22	62M	+1.1%	+9.4%
Q4 23	63M	+1.4%	+13.3%
Q3 25	69M	+9.2%	+25.8%
Q4 25	69M	+0.1%	+12.1%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 15	—	—
Q1 16	—	—
Q4 21	$108.7K	1K
Q2 22	$116.9K	1K
Q3 22	$107.2K	1K
Q4 23	$139.6K	970
Q3 25	$149.1K	930
Q4 25	$169.8K	930

Revenue / Employee